BJH - volume 11, issue Abstract Book BHS, february 2020
L. Nevejan , D. Selleslag MD, S. Huygens , B. Cauwelier MD, PhD, J. Emmerechts MD, PhD, H. Devos MD
BJH - volume 10, issue 6, october 2019
Y. Wouters PharmD, F. Nollet PhD, B. Cauwelier MD, PhD, J. Emmerechts MD, PhD, D. Selleslag MD, H. Devos MD
Patients lacking diagnostic criteria for myelodysplastic syndrome, but who show an unexplained persistent cytopaenia are classified as patients suffering from idiopathic cytopaenia of undetermined significance (ICUS). A fraction of these patients carry somatic mutations in genes which are also mutated in myeloid neoplasms. The significance of these mutations in ICUS patients is not well known and only few research papers have tried to correlate them with clinical outcome. ICUS patients carrying somatic mutations seem to have a higher progression rate to myeloid malignancies compared to unmutated patients. Some mutation profiles also show lower overall survival, similar to patients with (low-risk) myelodysplastic syndrome. Therefore, it seems useful to screen for somatic mutations in cytopaenic patients. The goal of this paper is to review recent literature regarding the significance of somatic mutations in cytopaenic patients and propose a screening protocol by evaluating a test protocol at the AZ Sint-Jan hospital Brugge-Oostende.
(BELG J HEMATOL 2019;10(6):231–40)
Read moreBJH - volume 10, issue 6, october 2019
E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys PharmD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD
Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.
(BELG J HEMATOL 2019;10(6):241–9)
Read moreBJH - volume 10, issue 6, october 2019
A. Louwagie PharmD, M. Tajdar PharmD, B. Cauwelier MD, PhD, H. Devos MD, J. Robbrecht MD, S. Van Erum MD, J. Emmerechts MD, PhD
We report a case of a falsely increased mean corpuscular volume (MCV) due to severe hyperglycaemia in a patient with diabetic ketoacidosis. This phenomenon results from in vitro swelling of hyperosmolar red blood cell size when diluted in an iso-osmolar buffer of a haematology analyser, and does not reflect a true macrocytosis in vivo. The magnitude of this effect is dependent on the glucose concentration of the sample and time of incubation prior to analysis. Haematology analysers from three different manufacturers were found equally sensitive to this phenomenon. Therefore, it is suggested to use reluctance when reporting and interpreting MCV results in the case of severe hyperglycaemia to avoid unnecessary additional investigation.
(BELG J HEMATOL 2019;10(6):250–4)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
B. Cauwelier MD, PhD, A. Van Haver , F. Nollet PhD, H. Devos MD, J. Emmerechts MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
L. Naesens , D. Selleslag MD, F. Nollet PhD, H. Devos MD
BJH - 2018, issue Abstract Book BHS, february 2018
A. Muyldermans , L. Florin , H. Devos MD, B. Cauwelier MD, PhD, J. Emmerechts MD, PhD
Top
